Patients with advanced-stage cancer suffering from treatment resistant anxiety and/or depression experienced significant reductions in both anxiety and depression with improvements of mood following a single guided psilocybin treatment, with no safety concerns or clinically significant adverse events. Other studies demonstrate efficacy of other psychedelic agents to relieve anxiety and stress disorders related to end of life. Therapy with psilocybin is well tolerated by seriously ill patients and, for some, remarkably effective in alleviating non-physical distress. Therapeutic benefits often persist long after any pharmacologic effect of the drug. It is time to support the legitimate therapeutic use of psychedelics.
To learn about Initiative 81 go on https://decrimnaturedc.org/initiative-81/